Annual Report for the fiscal year 2021
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Annual Report for the fiscal year of 2021. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “During the past year, we have seen promising results from multiple academic investigator-initiated phase II studies regarding indications in prostate, head and neck cancer as well as in neuroendocrine tumors. It is motivating to see how the interest in Curasight and our technology is continuously growing